2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
3
Neoplasms
3
Glioma
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Paraproteinemias
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Interventions
Rituximab
226
Cyclophosphamide
202
fludarabine phosphate
108
Peripheral Blood Stem Cell Transplantation
103
Filgrastim
87
Etoposide
76
Cytarabine
70
ibrutinib
68
Mycophenolic Acid
67
Bortezomib
66
Whole-Body Irradiation
63
Cyclosporine
63
Melphalan
59
Lenalidomide
59
Bendamustine Hydrochloride
58
Vincristine
53
Radiotherapy
53
fludarabine
52
Tacrolimus
50
Doxorubicin
48
Busulfan
48
Methotrexate
47
Antilymphocyte Serum
42
Prednisone
41
Carmustine
40
Dexamethasone
38
Granulocyte Colony-Stimulating Factor
33
venetoclax
32
acalabrutinib
31
zanubrutinib
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Mantle-Cell
×
CLR1404
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled